← Charles River Laboratories overview

Charles River Laboratories vs Personalis: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Charles River Laboratories (CRL)

Q3 2026
▲4

CRL's biotech recovery and AI deals drive 89% rally

  • AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.

    New collaboration that expands demand and technology positioning, directly driving future revenue.

  • Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.

    Analyst upgrade reflects improving fundamentals and boosts investor sentiment.

  • Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.

    Earnings beat and guidance raise confirm operational turnaround, a key price driver.

  • DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.

    Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

July 2026
▲4

CRL's biotech recovery and AI deals drive 89% rally

  • AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.

    New collaboration that expands demand and technology positioning, directly driving future revenue.

  • Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.

    Analyst upgrade reflects improving fundamentals and boosts investor sentiment.

  • Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.

    Earnings beat and guidance raise confirm operational turnaround, a key price driver.

  • DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.

    Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

Latest
▲4

CRL's biotech recovery and AI deals drive 89% rally

  • AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.

    New collaboration that expands demand and technology positioning, directly driving future revenue.

  • Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.

    Analyst upgrade reflects improving fundamentals and boosts investor sentiment.

  • Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.

    Earnings beat and guidance raise confirm operational turnaround, a key price driver.

  • DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.

    Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

Personalis Inc (PSNL)

Q3 2026
▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

  • Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.

    The takeover itself is the single biggest force setting PSNL's price.

  • Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.

    Legal challenges are a real counterweight that could change deal terms or timing.

  • Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.

    The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.

  • Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.

    This explains why PSNL trades near the deal price instead of rallying on takeover hopes.

August 2026
▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

  • Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.

    The takeover itself is the single biggest force setting PSNL's price.

  • Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.

    Legal challenges are a real counterweight that could change deal terms or timing.

  • Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.

    The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.

  • Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.

    This explains why PSNL trades near the deal price instead of rallying on takeover hopes.

Latest
▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

  • Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.

    The takeover itself is the single biggest force setting PSNL's price.

  • Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.

    Legal challenges are a real counterweight that could change deal terms or timing.

  • Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.

    The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.

  • Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.

    This explains why PSNL trades near the deal price instead of rallying on takeover hopes.